Abstract. Pancreatic cancer is the fourth commonest cause of cancer-related mortality across the world. Because of the poor response to conventional chemotherapy, small molecules, radiation therapy and surgery, development of new targeted therapies is necessary. In the present study, we have analyzed expression of the luteinizing hormone releasing hormone (LHRH) receptor in specimens of human pancreatic cancers. Furthermore, we have investigated in vitro and in vivo whether the cytotoxic LHRH agonist AEZS-108 (AN-152) induces apoptosis in human pancreatic cancer cells that express LHRH receptors. LHRH receptor expression in tumor specimens of human pancreatic cancers was assessed using immunohistochemistry. Cell proliferation was analyzed using the Alamar Blue proliferation assay. Induction of apoptosis was analyzed using the TUNEL assay and quantified by measurement of loss of mitochondrial membrane potential. In vivo experiments were performed using nude mice bearing xenografted human pancreatic tumors. Thirteen of 40 human pancreatic adenocarcinomas (32.5%) expressed LHRH receptors. We were able to show that treatment of LHRH receptor-positive MiaPaCa-2 and Panc-1 human pancreatic cancer cells with AEZS-108 (AN-152) resulted in apoptotic cell death in vitro. The antitumor effects could be confirmed in nude mice. inhibited the growth of xenotransplants of human pancreatic cancers in nude mice significantly, without any apparent side effects. The cytotoxic LHRH agonist AEZS-108 (AN-152) seems to be a suitable drug for treatment of LHRH receptor-positive human pancreatic cancers with little toxicity.
Introduction
The survival rate of patients with any stage of pancreatic cancer is poor. Pancreatic cancer spreads rapidly and is seldom detected in its early stages, which is a major reason why it is a leading cause of cancer death (1, 2) . Signs and symptoms of pancreatic cancer often do not occur until the disease is advanced. No specific tumor marker for the diagnosis of pancreatic cancer exists (3) . Pancreatic cancer is relatively resistant to conventional chemotherapeutic agents due to primary or secondary chemoresistance (4, 5) . Because of the poor response to conventional chemotherapy, small molecules, enzyme inhibitors, radiation therapy, and surgery, development of new targeted therapies is necessary. Some reports assume that pancreatic cancers express receptors for luteinizing hormone releasing hormone (LHRH, GnRH) (6) (7) (8) . Therefore, we considered that a therapy using LHRH receptors as a target may be applicable for LHRH receptorpositive pancreatic cancers.
The expression of LHRH and its receptor as a part of a negative autocrine/paracrine regulatory mechanism of cell proliferation has been demonstrated in a number of malignant tumors, including cancers of the endometrium, ovary and breast (9) . The LHRH receptor could be used for targeted chemotherapy to improve antitumor effects, reduce side effects compared with conventional systemic chemotherapy and to escape chemoresistance mechanisms of the tumors. LHRH agonists that are covalently linked to cytotoxic compounds bind specifically to LHRH receptors with their peptide moiety and act as chemotherapeutic agents after internalization of the ligand-receptor complex (10) . Thus, these conjugates selectively affect those cells that express LHRH receptors and exert fewer side effects than unconjugated cytotoxic agents. In addition, by entering the tumor cell via a receptor-mediated internalization, resistance mechanisms like multidrug resistance-1 (MDR-1) are circumvented (11, 12) . LHRH agonists that have a D-Lys moiety at position 6 offer an amino side chain for a convenient attachment of various cytotoxic compounds. Even bulky molecules can be linked to the ε-amino group of the D-Lys 6 moiety without a significant loss of binding affinity of the peptide portion to the receptors for LHRH (10 Stage  TNM  LHRH R   1  Male  65  Adenocarcinoma  2  III  T3N1M0  NO  2  Male  52  Adenocarcinoma  1  III  T3N1M0  YES  3  Female  45  Adenocarcinoma  2  III  T3N1M0  NO  4  Male  44  Adenocarcinoma  2  II  T3N0M0  NO  5  Male  47  Adenocarcinoma (sparse)  1  II  T3N0M0  NO  6  Male  55  Adenocarcinoma  2  II  T3N0M0  YES  7  Male  57  Adenocarcinoma (sparse) with necrosis  2  II  T3N0M0  NO  8  Male  34  Adenocarcinoma  1  II  T3N0M0  YES  9  Female  56  Adenocarcinoma  1  III  T3N1M0  NO  10  Male  42  Adenocarcinoma  1  IV  T2N0M1  YES  11  Female  39  Adenocarcinoma  2  II  T3N0M0  YES  12  Male  44  Adenocarcinoma  2  II  T3N0M0  NO  13  Male  59  Adenocarcinoma  2  II  T3N0M0  NO  14  Male  65  Adenocarcinoma (fibrofatty tissue)  -II  T3N0M0  NO  15  Female  67  Adenocarcinoma  -II  T3N0M0  NO  (chronic inflammation of pancreas tissue)  16  Male  53  Adenocarcinoma  1  II  T3N0M0  YES  17  Male  52  Adenocarcinoma  2  II  T3N0M0  NO  18  Female  72  Adenocarcinoma  1  II  T3N0M0  NO  19  Female  58  Adenocarcinoma  2  II  T3N0M0  YES  20  Male  41  Adenocarcinoma  2  II  T3N0M0  NO  21  Male  51  Adenocarcinoma  2  II  T3N0M0  YES  22  Male  41  Adenocarcinoma (sparse)  -II  T3N0M0  NO  23  Female  68  Adenocarcinoma  2  II  T3N0M0  NO  24  Female  41  Adenocarcinoma  2  II  T3N0M0  NO  25  Female  72  Adenocarcinoma  2  II  T3N0M0  YES  26  Female  76  Adenocarcinoma with necrosis  2  III  T4N0M0  YES  27  Male  52  Adenocarcinoma  2  II  T3N0M0  NO  28  Female  60  Adenocarcinoma  2  III  T4N0M0  NO  29  Male  76  Adenocarcinoma (sparse)  2  II  T3N0M0  NO  30  Male  78  Adenocarcinoma  2  II  T3N0M0  NO  31  Male  41  Adenocarcinoma  2  III  T4N1M0  NO  32  Female  62  Adenocarcinoma  3  II  T3N0M0  NO  33  Male  51  Adenocarcinoma (sparse)  -II  T3N0M0  NO  34  Male  50  Adenocarcinoma  3  III  T3N1bM0  YES  35  Male  60  Adenocarcinoma  2  III  T3N1M0  NO  36  Female  53  Adenocarcinoma  2  II  T3N0M0  NO  37  Male  59  Adenocarcinoma  2  II  T3N0M0  NO  38  Male  56  Adenocarcinoma  3  III  T2N1bM0  YES  39  Female  60  Adenocarcinoma  3  IV  T2N1M1  YES  40  Female  66  Adenocarcinoma  -II  T3N0M0 (11, 12) . In cancer cell lines that do not express LHRH receptors, no intracellular accumulation of AEZS-108 (AN-152) could be detected (13) .
In the present study, we have analyzed the expression of the LHRH receptor in specimens of human pancreatic cancers. Furthermore, we have investigated in vitro and in vivo whether the cytotoxic LHRH agonist AEZS-108 (AN-152) may be a suitable drug for an efficacious and less toxic therapy for human pancreatic cancers that express LHRH receptors.
Materials and methods
Cell lines and culture conditions. The pancreatic cancer cell lines MiaPaCa-2 and Panc-1 were obtained from the American Type Culture Collection (ATCC, Manassas, VA). MIAPaCa-2 cells were derived from epithelial tumor tissue of the pancreas obtained from a 65-year-old Caucasian male. Panc-1 cells were derived from a ductal epithelioid carcinoma of the pancreas obtained from a 56-year-old Caucasian male. In order to guarantee the identity of the cell lines over the years, the cells were expanded after purchase and aliquots were stored in liquid nitrogen. Every half year a new frozen stock was opened and expanded to carry out the experiments. The cells were cultured at 37˚C in a humidified atmosphere of 5% CO 2 in air as previously described (14) (15) (16) . Human tissues. To analyze LHRH receptor expression in specimens of human pancreatic cancers we used human tissue arrays (US Biomax, Rockville, MD, USA) containing paraffinembedded human normal and malignant pancreatic tissues specimens, whose characteristics are outlined in Table I . Written, informed consent for the use of human tissues was obtained in accordance with the ethics guidelines that were effective at the time of collection and processing.
Animals. Female athymic (nude) mice (CD1 nu/nu), 6-8 weeks old on arrival, were obtained from Charles River (Sulzfeld, Germany). The mice were housed in sterile cages in a temperature-controlled room with 12-h light/12-h dark schedule and were fed autoclaved chow and water ad libitum. All experiments were performed according to the German ethics guidelines and the German laws for protection of animals.
Immunohistochemistry. The tissue array slides were deparaffinized and rehydrated. Antigens were retrieved by incubation with 0.01M citrate buffer (pH 6.0) in a microwave (700 W) for 5 min. Endogenous peroxidase activity was quenched by treatment with 3% hydrogen peroxide solution for 6 min. After washing in PBS, the slides were treated with polyclonal rabbit anti-human LHRH receptor antiserum (17) in a 1:10,000 dilution in 1% BSA in 10 mM Tris, pH 8.0, 500 mM NaCl and 0.1% Tween-20 (TBST) for 1 h and, after being washed, were detected with the ready-to-use secondary horseradish peroxidase-conjugated anti-rabbit IgG antibody detection system according to the instructions of the supplier (Zymed Laboratories, San Francisco, CA, USA). Controls were performed by substitution of the primary antiserum with pre-immune serum of the same rabbit. Counterstaining was performed using Meyer's hematoxylin for 10 sec. The slides Stage  TNM  LHRH R   47  Male  30  Normal pancreas tissue  ---NO  48  Male  40  Normal pancreas tissue  ---NO  49  Male  35  Normal pancreas tissue  ---NO  50  Female  21 Normal pancreas tissue ---NO Grade 1 or well-differentiated, cells appear normal and are not growing rapidly. Grade 2 or moderately-differentiated, cells appear slightly different than normal. Grade 3 or poorly differentiated, cells appear abnormal and tend to grow and spread more aggressively. TNM grading: Tx, primary tumor cannot be assessed; T0, no evidence of primary tumor; Tis, carcinoma in situ; intraepithelial or invasion of lamina propria; T1, tumor invades submucosa; T2, tumor invades muscularis propria; T3, tumor invades through muscularis propria into subserosa or into non-peritonealized pericolic or perirectal tissues; T4, tumor directly invades other organs or structures and/or perforates visceral peritoneum. Nx, regional lymph nodes cannot be assessed; N0, no regional lymph node metastasis; N1, metastasis in 1 to 3 regional lymph nodes; N2, metastasis in 4 or more regional lymph nodes; Mx, distant metastasis cannot be assessed; M0, no distant metastasis; M1, distant metastasis.
were then dehydrated, cleared, mounted with Permount and studied by light microscopy.
Proliferation assay. Cells (500/well) were plated into 96-well plates (Falcon, Heidelberg) in 100 µl phenol redfree DMEM/5% FCS (Biochrom, Berlin, Germany) 2 mM glutamine, 50 U/ml penicillin/streptomycin, 2.5 µg/ml amphotericin B, and 1:100 non-essential amino acids. After cell attachment, 100 µl medium or 100 µl AEZS-108 (AN-152) solution at increasing final concentrations of 10 -11 -10 -5 M was added to the wells in six replicates and incubated for 5 days at 37˚C, 5% CO 2 . Cell number was determined by a colorimetric assay using Alamar Blue (Biosource, Solingen, Germany). The optical density (OD) of the reduced dye was assessed at 570 vs. 630 nm after 4 h at 37˚C.
Mitochondrial membrane potential.
For determination of AEZS-108 (AN-152)-induced loss of mitochondrial membrane potential, cells were treated without or with AEZS-108 (AN-152; 10 -9 and 10 -7 M) for 72 h. After incubation, the cells were washed with PBS once and the mitochondrial membrane potential was detected using the JC-1 mitochondrial membrane potential detection kit according to the instructions of the manufacturer (Biotium, Hayward, CA, USA).
TUNEL assay. The terminal deoxynucleotidyl transferasemediated nick-end labeling (TUNEL) assay was used to monitor DNA fragmentation as a measure of apoptosis in tumor cells grown on slides after treatment with 10 -7 M AEZS-108 (AN-152) for 12-48 h. The cells were fixed using 4% paraformaldehyde in PBS at 4˚C overnight and stained according to the recommendations of the manufacturer (DeadEnd Colorimetric TUNEL System, Promega, Mannheim, Germany). Counterstaining was performed using Meyer's hematoxylin for 10 sec.
In vivo studies. Tumors were initiated by subcutaneous injection of 1x10 7 Statistical analysis. All experiments were repeated three times with different passages of the respective cell lines. The data were analyzed for significant differences by one-way analysis of variance followed by the Student-Newman-Keuls' test for comparison of individual groups, after a Bartlett test had shown that variances were homogeneous.
Results

LHRH receptor expression.
Forty human pancreatic cancer specimns and 10 normal pancreatic tissues were analyzed for LHRH receptor expression (Table I) . Twenty-seven human pancreatic cancer specimens (67.5%) were LHRH receptornegative. Thirteen human pancreatic cancer specimens (32.5%) showed LHRH receptor expression. None of the normal pancreas tissues showed LHRH receptor antigenicity. (Fig. 1) .
Effects of AEZS-108 (AN-
After treatment of MiaPaCa-2 human pancreatic cancer cells (Fig. 1A) 
Effects of AEZS-108 (AN-152) on mitochondrial membrane
potential. Induction of apoptosis was analyzed by measurement of the loss of the mitochondrial membrane potential (∆Ψ). Treatment of MiaPaCa-2 and Panc-1 human pancreatic cancer cells with increasing concentrations (10 -9 -10 -5 M) of AEZS-108 (AN-152) for 72 h resulted in a reduction of the ∆Ψ ( Fig. 2A and B) .
Treatment of MiaPaCa-2 human pancreatic cancer cells ( Fig. 2A) (AN-152) on DNA fragmentation. The effects of AEZS-108 (AN-152) on induction of apoptotic cell death could be confirmed by visualization of DNA fragmentation ( Fig. 2C and D) . Treatment of MiaPaCa-2 human pancreatic cancer (Fig. 2C) and Panc-1 (Fig. 2D) human pancreatic cancer cells with 2x10 -7 M of AEZS-108 (AN-152) resulted in a clear increase of apoptotic cells.
Effects of AEZS-108
Effects of AEZS-108 (AN-152) on tumor growth in vivo.
To show the proof-of-principle of an antitumor therapy using AEZS-108 (AN-152), nude mice bearing xenografted MiaPaCa-2 and Panc-1 human pancreatic tumors s.c. were treated with AEZS-108 (AN-152) (Fig. 3) .
In vivo experiment 1. In experiment 1 (Fig. 3A) 
Discussion
Previous studies have shown that AEZS-108 (AN-152) induces apoptotic cell death in LHRH receptor-positive human endometrial, ovarian and breast cancer cells in vitro and in vivo (13, 18, 19) . In addition, we could demonstrate that AEZS-108 (AN-152)-induced apoptosis in human endometrial, ovarian and breast cancer cell lines is independent of the multidrug resistance-1 (MDR-1) system (11, 12) . Because of the LHRH receptor-mediated entry of AEZS-108 (AN-152) into the cancer cells, AEZS-108 (AN-152) may overcome chemoresistance, which is a major drawback of systemic therapy of these malignancies by anthracyclines and other chemotherapeutic agents (11, 12) . The poor prognosis of pancreatic cancer is believed to be partly due to primary or secondary chemoresistance of specific subgroups of pancreatic cancer cells, namely those with an epithelial-mesenchymal transition (EMT) phenotype and cancer stem cells (20) .
Some reports have shown that pancreatic cancers express LHRH receptors (6) (7) (8) . Therefore, we considered that a therapy using LHRH receptors as a target may be applicable for LHRH receptor-positive pancreatic cancers. First, we analyzed LHRH receptor expression in tumor specimens of human pancreatic cancers using immunohistochemistry. We could show that 13 of 40 human pancreatic cancers (32.5%) expressed LHRH receptors. None of the normal pancreatic tissues (n=10) showed LHRH receptor expression. Friess et al detected LHRH binding sites in 57% of patients (n=23) with ductal pancreatic cancer and in 1 of 11 normal pancreatic tissues (9.1%) (6) . These discrepancies may be due to differences in the techniques used (immunohistochemistry of paraffin embedded tissues vs.
125 I-[t-butyl-D-serin 6 ]LHRH binding assay of homogenized tissues). Since most organs including the normal pancreas and hematopoietic stem cells do not express LHRH receptors (19) , these receptors could be used as a target site for well tolerable therapies.
Pancreatic adenocarcinoma, the most common type of pancreatic cancer, is the most aggressive of all cancers. Pancreatic cancer spreads rapidly and is seldom detected in its early stages (1, 2) . By the time pancreatic cancer is diagnosed, most patients have already developed distant metastases. For patients with advanced cancers, the overall survival rate of all stages is less than 1% at 5 years with most patients dying within 1 year (21) (22) (23) (24) . Because pancreatic cancer is also relatively resistant to medical treatment, the therapeutic options are very limited. Treatment with the cytotoxic LHRH agonist AEZS-108 (AN-152) could be a new option for the therapy of pancreatic cancer as approximately 29% of these tumors (n=40) may express LHRH receptors.
In the present study, we could demonstrate that treatment of LHRH receptor-positive MiaPaCa-2 and Panc-1 human pancreatic cancer cells with the cytotoxic LHRH agonist AEZS-108 (AN-152) in vitro resulted in apoptotic cell death via loss of mitochondrial membrane potential. In addition, we could show the proof-of-principle of an antitumor therapy using AEZS-108 (AN-152) in vivo in nude mice bearing s.c. xenografts of human LHRH receptor-positive pancreatic cancers. Nude mice bearing MiaPaCa-2 or Panc-1 human pancreatic cancers were treated without or with AEZS-108 (AN-152) or with doxorubicin. The tumor growth of the mice receiving therapy with AEZS-108 (AN-152) was significantly reduced. Toxic side effects were not observed. Equimolar doses of doxorubicin were nearly ineffective in inducing apoptosis in LHRH receptor-positive human pancreatic tumors and in reducing their growth in vivo. Our findings could be the basis for further evaluation in clinical trials. In a current phase II study, AEZS-108 (AN-152) was found to be active and welltolerated in patients with heavily pretreated platinum-and taxane-resistant LHRH receptor-positive ovarian cancer (25) . Patients with any stage of pancreatic cancer can appropriately be considered candidates for clinical trials because of the poor response to chemotherapy, radiation therapy, and surgery as conventionally used.
In conclusion, we were able to show that about 29% of human pancreatic cancers express LHRH receptors and that AEZS-108 (AN-152) induces apoptotic cell death in LHRH receptor-positive MiaPaCa-2 and Panc-1 human pancreatic cancer cells in vitro and in vivo. Apoptosis induced by AEZS-108 (AN-152) is mediated through the intrinsic apoptotic pathway via loss of mitochondrial membrane potential.
Thus, the cytotoxic LHRH agonist AEZS-108 (AN-152) seems to be a suitable drug for targeted chemotherapy for LHRH receptor-positive human pancreatic cancers.
